Global Non-Small Cell Lung Cancer Therapeutics Market to Reach $13.3 Billion by 2015, According to New Report by Global Industry Analysts
GIA announces the release of a comprehensive global report on Lung Cancer Therapeutics market. World market for non-small cell lung cancer therapeutics is expected to reach $13.3 billion by 2015 fueled by rising incidence of lung cancer, improved understanding of non-small cell lung cancer, and the development of new treatments targeted at growth factor pathways.
San Jose, California (PRWEB) June 24, 2009 -- Lung cancer is one of the most common types of cancers across the world, which not only increases mortality rates but also enhances the financial burden on the society. The global market for lung cancer therapeutics is driven by factors such as line extensions for existing products, introduction of innovative products, and advancements in biotechnology. Cytotoxics such as cisplatin, carboplatin, docetaxel (Taxotere), paclitaxel and gemcitabine (Gemzar) continue to dominate the lung cancer pharmaceuticals market, although targeted therapies have begun to create an impact on the market. The lack of data proving the clinical efficacy of targeted drugs contributes to the continued use of cytotoxics for lung cancer treatment.
Tarceva is expected to continue its dominance in the global market for lung cancer therapeutics, while the approvals of Avastin, Erbitux, Zactima, as well as other novel therapies are expected to offer enhanced growth opportunities. Though the patents of three major chemotherapy drugs - Paraplatin (carboplatin), Taxotere (docetaxel) and Gemzar (gemcitabine) are set to expire before 2012, the emergence of new drugs/therapies is expected to offset the revenue decline.
The United States and Europe collectively dominate the global non-small cell lung cancer therapeutics market, as stated in the new market research report. The market for non-small cell lung cancer therapeutics in the United States is driven by the introduction of new immunotherapies and increased uptake of VEGF (vascular endothelial growth factor) inhibitors such as Avastin. In addition, the introduction of targeted drugs such as Erbitux and Zactima is expected to boost sales of non-small cell lung cancer therapy market. The introduction of Pfizer's ProMune for advance stage NSCLC and Merck Serono's Stimuvax for stage III NSCLC is expected to boost growth prospects in the near term.
Leading players in the global lung cancer therapeutics market include AstraZeneca Plc, Bristol-Myers Squibb, Eli Lilly & Co., F. Hoffmann-La Roche Ltd, Genentech Inc., GlaxoSmithKline Plc, Novartis Pharmaceuticals Corporation, OSI Pharmaceuticals Inc., and Sanofi-Aventis, among others.
The report titled "Lung Cancer Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts, Inc., provides a review of market trends, product introductions/innovations, and recent industry activity. The report analyzes market data and analytics for Non-Small Cell Lung Cancer Therapeutics across the following regions - United States, Europe, and Rest of World.
For more details about this comprehensive market research report, please visit - http://www.strategyr.com/Lung_Cancer_Therapeutics_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press (at) StrategyR (dot) com
Web Site http://www.StrategyR.com/
###
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/U3VtbS1TcXVhLUluc2UtTG92ZS1JbnNlLUNvdXAtWmVybw==
Bookmark -
Del.icio.us |
Furl It |
Technorati |
Ask |
MyWeb |
Propeller |
Live Bookmarks |
Newsvine |
TailRank |
Reddit |
Slashdot |
Digg |
Stumbleupon |
Google Bookmarks |
Sphere |
Blink It |
Spurl
|
